Alvotech
Alvotech's revenue rose 19.7% to $586 million in fiscal 2025. Its operating margin was 13.3%, down from 14.2% a year earlier. Free cash flow was −$115 million. The diluted share count rose 8.7%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
What Alvotech does
Alvotech develops and makes biosimilar medicines, which are biological medicines highly similar to an existing approved biologic whose patent protection has ended. It says it focuses solely on biosimilars, for patients worldwide, and treats autoimmune, eye, respiratory and blood diseases and cancer.
It does the work in house, from development to manufacturing at its main site in Reykjavik, Iceland, and says it has invested over $2 billion in this platform. It does not sell most products itself. It licenses its biosimilars to commercial partners such as Teva, Advanz Pharma and Dr. Reddy's, and earns milestone payments and royalties on their sales.
It currently has five approved products and thirty more candidates in its pipeline. It competes with the companies that make the original drugs and with other biosimilar makers. It is also working with Dr. Reddy's on a biosimilar to Keytruda for global markets.
Its biggest risks, as it describes them
- Developing and making biosimilars is slow, costly and uncertain, and its products may not win approval.
- Its dependence on commercial partners to sell its products.
- Doubt about its ability to keep operating without more financing, and the dilution that could follow.
- Problems producing enough product, or interruptions at its manufacturers and service providers.
- Claims that it or a partner infringes patents owned by others.
Income statement
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 18 | 66 | 11 | 51 | 172 |
| Debt incl. finance leases | 401 | 765 | 960 | 1,069 | 1,299 |
| Net debt (negative means net cash) | 383 | 698 | 949 | 1,017 | 1,127 |
| Net debt to EBITDA | — | — | — | 10.1x | 9.7x |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −2.0x | −1.8x | −1.3x | 0.2x | 0.5x |
| Current ratio | 1.1x | 1.4x | 0.8x | 2.4x | 1.9x |
| Quick ratio | 0.7x | 0.9x | 0.5x | 1.7x | 1.2x |
Cash flow
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 2 of 9 | 5 of 9 | 3 of 9 |
| Rule of 40 | −367.7% | 376.2% | 0.2% |
| Altman Z'' | −11.06 | −4.98 | −3.91 |
| Accruals ratio | −26.9% | 0.5% | 5.8% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Pass |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Pass | Fail | Fail |
| Debt fell relative to assets | Fail | Pass | Pass |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Pass | Fail |
| Revenue rose relative to assets | Fail | Pass | Fail |
| F-score | 2 of 9 | 5 of 9 | 3 of 9 |
Compare
Put Alvotech side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Alvotech | FY25 | 19.7% | 13.3% | −19.6% | 5.4% | 9.7x | 3 | |
| TG Therapeutics | FY25 | 87.3% | 20.0% | −4.0% | 29.0% | 0.4x | 4 | Compare |
| ADMA Biologics | FY25 | 19.6% | 37.5% | 5.5% | 39.5% | −0.1x | 5 | Compare |
| Ascendis Pharma A/S | FY25 | 98.0% | −18.9% | — | — | — | 5 | Compare |
| Repligen | FY25 | 16.4% | 7.5% | 12.7% | 2.4% | −1.7x | — | Compare |
6 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 67 | 37 | 83 | 91 | 490 | 586 |
| Revenue growth | — | −44.8% | 125.8% | 10.1% | 435.6% | 19.7% |
| Gross profit | — | 37 | 19 | −69 | 304 | 351 |
| Research and development | 148 | 191 | 181 | 211 | 171 | 184 |
| Operating income | −138 | −236 | −346 | −355 | 70 | 78 |
| Net income | −170 | −102 | −514 | −552 | −232 | 28 |
| Diluted EPS (US$) | −1.82 | −0.92 | −2.60 | −2.43 | −0.87 | 0.10 |
| Diluted shares (millions) | 94 | 111 | 198 | 227 | 268 | 291 |
| Cash flow | ||||||
| Cash from operations | −74 | −228 | −312 | −312 | −237 | −50 |
| Capital expenditure | 8 | 20 | 38 | 33 | 54 | 64 |
| Free cash flow | −82 | −249 | −350 | −345 | −290 | −115 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | — | 0 | 10 | 18 | 8 | 7 |
| Balance sheet at fiscal year end | ||||||
| Cash and short-term investments | 32 | 18 | 66 | 11 | 51 | 172 |
| Debt incl. finance leases | — | 401 | 765 | 960 | 1,069 | 1,299 |
| Total assets | — | 598 | 828 | 950 | 1,221 | 1,487 |
| Total liabilities | — | 734 | 1,393 | 1,883 | 1,634 | 1,772 |
| Shareholders' equity | −867 | −136 | −564 | −932 | −413 | −284 |
| Margins and ratios | ||||||
| Gross margin | — | 100.0% | 22.8% | −75.9% | 62.2% | 59.8% |
| Operating margin | −206.5% | −640.3% | −417.2% | −388.1% | 14.2% | 13.3% |
| Net margin | −255.3% | −276.0% | −618.5% | −603.4% | −47.4% | 4.8% |
| Free cash flow margin | −122.8% | −676.1% | −421.9% | −377.8% | −59.3% | −19.6% |
| Rule of 40 (growth + FCF margin) | — | −720.9% | −296.1% | −367.7% | 376.2% | 0.2% |
| Return on capital | — | — | −143.5% | — | 17.7% | 5.4% |
| Return on equity | — | — | — | — | — | — |
| Return on assets | — | — | −72.0% | −62.0% | −21.4% | 2.1% |
| Net debt to EBITDA | — | — | — | — | 10.1x | 9.7x |